Phase 2, Single-Arm, Open-Label, Multi-Center Trial of Second-Line Panitumumab Monotherapy in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Panitumumab (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- Acronyms PRISM
- Sponsors Amgen
- 15 Dec 2017 Status changed from active, no longer recruiting to completed.
- 01 Jun 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 14 Dec 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.